Fluoroquinolones in the management of community-acquired pneumonia
Summary Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community‐acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicro...
Saved in:
Published in | International journal of clinical practice (Esher) Vol. 64; no. 3; pp. 378 - 388 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.02.2010
Wiley-Blackwell Hindawi Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community‐acquired pneumonia (CAP).
Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines.
Results: Randomised clinical trials of respiratory fluoroquinones (moxifloxacin, levofloxacin and gemifloxacin) in the treatment of CAP were identified and analysed. The bacteriology of CAP, and susceptibility rates, resistance rates and pharmacokinetic and pharmacodynamic properties of fluoroquinolones against causative pathogens in CAP, and adverse event profiles of these agents were described. Respiratory fluoroquinones have broad‐spectrum antibacterial activities against common causative pathogens in CAP and provide an important treatment option as monotherapy for outpatients with comorbidities and inpatients who are not admitted to the intensive care unit (ICU), including those with risk factors of drug‐resistant Streptococcus pneumoniae. For treatment of ICU patients with severe CAP, it is recommended that fluoroquinolones be used in combination with a β‐lactam. Recent studies also demonstrated a more rapid resolution of clinical symptoms with the use of highly potent respiratory fluoroquinolones.
Discussion: Appropriate use of fluoroquinolone agents may shorten the duration of antimicrobial therapy and the length of hospital stay and contribute to the decreased development of resistance in patients with CAP. Adverse event profiles of these agents should be considered to facilitate the selection of an appropriate fluoroquinolone for appropriate CAP patients.
Conclusion: The fluoroquinolone class, specifically those with adequate activity against respiratory pathogens, represents an important and convenient treatment option for patients with CAP. |
---|---|
Bibliography: | ark:/67375/WNG-WWQNL61C-N ArticleID:IJCP2239 istex:9B0F78253035A6A9A41145123336E8226F0D4F3F Disclosures Dr Albertson has served on Speakers Bureau for Boehringer Ingelheim and GlaxoSmithKline (GSK) and Schering‐Plough, and has received research funding from Pfizer. Dr Dean has served on Advisory boards for Forest, Advanced Life Sciences and Schering‐Plough, and has received research funding via contracts with Intermountain Healthcare, Aggenix, Pfizer and Novartis, and employment from Intermountain Healthcare. Dr El Solh has nothing to disclose. Dr Gotfried has served on Advisory Boards for GSK and Schering‐Plough, and has received research support from Ortho‐McNeil, Pfizer and GSK. Dr Carl Kaplan has nothing to disclose. Dr Niederman has received honoraria or consulted for Bayer, Schering‐Plough, Merck, Pfizer, Johnson and Johnson and Nektar, and has received grants from Nektar. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1368-5031 1742-1241 |
DOI: | 10.1111/j.1742-1241.2009.02239.x |